
Claims

We claim :

1. A compound of the Formula I:



(I)

wherein:

X is NH;

W is O;

R is Cl and a 1,3 dioxoalkylene chain bound to the phenyl ring so as to form 1,3-dioxolane;

R_1, R_2, R_3 each independently is H;

n is 0;

or

a pharmaceutically acceptable salt, or tautomer thereof.

2. A pharmaceutical composition comprising a compound of Formula I according to claim 1, and a physiologically acceptable carrier.

3. A composition of claim 2 wherein the compound is present in an amount of from 0.1 – 1000 mg.

4. A composition of claim 3 wherein the compound is present in an amount from 0.1 – 500 mg.

5. A composition of claim 2 that is the form of a tablet, capsule, powder, suspension, aerosol, spray, granulate, solution, or paste.

6. A composition of claim 2 that is administered orally, parenterally, intradermally, intranasally, subcutaneously, intrabuccally, intravenously, intramuscularly, or iontophoretically.

7. Use of a compound of claim 1 for the preparation of a medicament for the treatment of a proliferative, autoimmune, anti-inflammatory or infectious diseases.

8. The use of claim 7 wherein the disorder is selected from the group consisting of angiogenesis, cancers, tumor formation, arteriosclerosis, ocular disease, arthritis, thrombosis, fibrosis, glomerulonephritis, psoriasis, restenosis, transplant rejection, cirrhosis, viral and bacterial infections, and autoimmune disease.

9. The use of claim 8 wherein the disease is a cancer.


10. The use of claim 7 wherein administration of the compound is simultaneous, sequential or in alternation with administration of at least one other active drug agent.

11. A kit comprising separate packets, the first having a therapeutically effective amount of a pharmaceutical composition according to claim 2, and the second having a therapeutically effective amount of a pharmaceutical composition comprising a further pharmaceutically active ingredient.


Claims

We claim:


1. A compound of the Formula III, IV, or I:



(III)



(IV)



(I)

wherein:

X is NH, NH-C(=O), (-C=O)NH, NH-C(=O)NH, O, S, SO_2NH, CH_2, -C≡C-, or –HC=CH

Q is NH(C=Y) or (C=Y)NH;

Y and W each independently is O, S, or NH;

R is H, halo, cyano, nitro, alkyl, trifluoromethyl, heteroalkyl, OR', SR' and NR'R", where R' and R" each independently are H, alkyl, haloalkyl, alkylhalo, or heteroalkyl; or R is an heteroalkyl chain that optionally is bound at either end to adjoining carbon atoms of the phenyl ring to which it is attached, thereby forming a bicyclic ring structure;

R_1, R_2, R_3 each independently is H, SH or an ether or oxidated form of sulfur; halo, nitro, amino, alkyl, formyl, hydroxy, hydroxyalkyl, alkoxy, cyano, carboxy, carboxylic acid, a carboxylic acid ester, a carboxylic acid amide such as -(C=O)-(NrxRy), acetic acid, acetic acid ester, acetic acid amide including an acetic acid amide having substitutions -(C=O)-N(RxRy), substituted or unsubstituted aryl, heterocyclic-alkoxy, substituted or unsubstituted heterocycle or heteroaryl, alkylamino, dialkylamino, alkylaminoalkyl, dialkylaminoalkyl, alkyldiamino, alkylaminoalkoxy, alkyldiaminoalkoxy, heterocyclic-alkoxy, alkylamino amide, dialkylamino amide carboxylic acid ester, hydroxyalkyl-hydroxy, hydroxy-alkylamide ester, dihydroxy-alkylamide ester, hydroxyalkylamide acetic acid; wherein Rx and Ry each independently may be H, alkyl, aminoalkyl, dialkylaminoalkyl, aryl-aminoalkyl, carbocycle-aminoalkyl, or heteroaryl-amino alkyl; and wherein the two groups bonded to the N atom of an aminoalkyl group may, together with the N atom to which they are bound, join to form a heterocyclic group;

n is 1, 2, 3 or 4, with the proviso that n may = 0 when X is other than oxygen;

A is a 3-7 membered ring, saturated or unsaturated, optionally having 1 or more heteroatoms and further optionally substituted;

Cy is selcted from the group consisting of an unsubstituted or substituted cycloalkyl, bicycloalkyl, aryl, heterocycle and heteroaryl;

Z is H, SH, hydroxy, halo, amino, acyl, formyl, alkylamino-heterocycle, dialkylamino-heterocycle, alkylamino-alkylamino, dialkylamino-alkylamino, alkylamino-alkoxy, dialkylamino-alkoxy, heterocyclic alkoxy, C_{1-6} alkyl ester, phenyl, benzoyl, phenyl alkyl ketone, alkyl propanoyl, dialkyl alkanamide, acetic acid, or acetic acid amides;

Z' is CH or N; or

a pharmaceutically acceptable salt, prodrug, hydrate, solvate, racemic mix, tautomer or enantiomer thereof.

2. The compound of claim 1, Formula (I), wherein:

X is NH, NH-C(=O), (-C=O)NH, NH-C(=O)NH, O, S, SO_2NH, CH_2, -C≡C-, or –HC=CH;

W is O, S, CH_2, or NH;

R is H, halo, cyano, nitro, alkyl, trifluoromethyl, heteroalkyl, OR', SR' and NR'R", where R' and R" each independently are H, alkyl, haloalkyl, alkylhalo, or heteroalkyl; or R is an heteroalkyl chain that optionally is bound at either end to adjoining carbon atoms of the phenyl ring to which it is attached, thereby forming a bicyclic ring structure;

R_1, R_2, R_3, each independently is H, SH or an ether or oxidated form of sulfur; halo, nitro, amino, alkyl, formyl, hydroxy, hydroxyalkyl, alkoxy, cyano, carboxy, carboxylic acid, a carboxylic acid ester, a carboxylic acid amide such as -(C=O)-N(RxRy), acetic acid, acetic acid ester, acetic acid amide including an acetic acid amide having substitutions -(C=O)-N(RxRy), substituted or unsubstituted aryl, heterocyclic-alkoxy, substituted or unsubstituted heterocycle or heteroaryl, alkylamino, dialkylamino, alkylaminoalkyl, dialkylaminoalkyl, alkyldiamino, alkylaminoalkoxy, alkyldiaminoalkoxy, heterocyclic-alkoxy, alkylamino amide, dialkylamino amide carboxylic acid ester, hydroxyalkyl-hydroxy, hydroxy-alkylamide ester, dihydroxy-alkylamide ester, hydroxyalkylamide acetic acid, wherein Rx and Ry each independently may be H, alkyl, aminoalkyl, dialkylaminoalkyl, aryl-aminoalkyl, carbocycle-aminoalkyl, or heteroaryl-amino alkyl; and wherein the two groups bonded to the N atom of an aminoalkyl group may, together with the N atom to which they are bound, join to form a heterocyclic group;

n is 1, 2, 3 or 4, with the proviso that n may = 0 when X is other than oxygen; or

a pharmaceutically acceptable salt, prodrug, hydrate, solvate, racemic mix, tautomer or enantiomer thereof.

3. The compound of claim 2 wherein the residues not designated in greater detail have the meaning indicated in claim 2, but in which

in Subformula Ia W is O, X is NH, n = 0, and R is H;

in Subformula Ib W is O, X is NH, n =0, and R simultaneously is Cl and a 1,3 dioxoalkylene chain bound to the phenyl ring so as to form 1,3-dioxolane;

in Subformula Ic W is O, X is O, n = 1, and R is H;

in Subformula Id W is S, X is CH_2, n = 0, and R is Cl;

in Subformula Ie ~~W is NH,~~ X is CH_2, ~~n = 0, and R is F;~~

in Subformula If ~~W is O,~~ X is NH, n = 1, and R is di-fluoro.

4. The compound of claim 1, Formula III, wherein:

X is NH, NH-C(=O), NH-CH_2, (-C=O)NH, NH-C(=O)NH, O, S, SO_2NH, CH_2, -C≡C-, or –HC=CH-;

Q is NH(C=Y) or (C=Y)NH;

Y and W ~~each independently~~ is O~~, S, or NH~~;

A is a 3-7 membered ring, saturated or unsaturated, optionally having 1 or more heteroatoms ~~and further optionally substituted~~;

Cy is selcted from the group consisting of ~~an unsubstituted or substituted~~ cycloalkyl, bicycloalkyl such as norbornyl, aryl, heterocycle and heteroaryl;

R_1, R_2, R_3, each independently is H, SH or an ether or oxidated form of sulfur; halo, nitro, amino, alkyl, formyl, hydroxy, hydroxyalkyl, alkoxy, cyano, carboxy, carboxylic acid, a carboxylic acid ester, a carboxylic acid amide such as -(C=O)-N(RxRy), acetic acid, acetic acid ester, acetic acid amide including an acetic acid amide having substitutions -(C=O)-N(RxRy), substituted or unsubstituted aryl, heterocyclic-alkoxy, substituted or unsubstituted heterocycle or heteroaryl, alkylamino, dialkylamino, alkylaminoalkyl, dialkylaminoalkyl, alkyldiamino, alkylaminoalkoxy, alkyldiaminoalkoxy, heterocyclic-alkoxy, alkylamino amide, dialkylamino amide carboxylic acid ester, hydroxyalkyl-hydroxy, hydroxy-alkylamide ester, dihydroxy-alkylamide ester, hydroxyalkylamide acetic acid, wherein Rx and Ry each independently may be H, alkyl, aminoalkyl, dialkylaminoalkyl, aryl-aminoalkyl, carbocycle-aminoalkyl, or heteroaryl-amino alkyl; and wherein the two groups bonded to the N atom of an aminoalkyl group may, together with the N atom to which they are bound, join to form a heterocyclic group; or a pharmaceutically acceptable salt, ~~prodrug,~~ hydrate, solvate, tautomer, racemic mix, or enantiomer thereof.

5. The compound of claim 4 wherein the residues not designated in greater detail have the meaning indicated in claim 4, but in which

in Subformula IIIa Q is NH(C=O), W is O, X is NH, and A and Cy are phenyl;

~~in Subformula IIIb Q is NH(C=O) and Cy is methoxyphenyl;~~

in Subformula IIIc Q is NH(C=O) and Cy is methylphenyl;

in Subformula IIId Q is NH(C=O) and Cy is fluoro, trifluoromethyl phenyl;

in Subformula IIIe Q is NH(C=O) and Cy is chlorophenyl or dichlorophenyl;

in Subformula IIIf Q is NH(C=O) and Cy is naphthyl;

in Subformula IIIg Q is NH(C=O) and Cy is norbornyl;

in Subformula IIIh Q is NH(C=O) and Cy is trifluoromethoxyphenyl;

in Subformula IIIj Q is (C=O)NH, W is O, X is NH, and A and Cy are phenyl;

in Subformula IIIk Q is (C=O)NH and Cy is methoxyphenyl;

in Subformula IIIm Q is (C=O)NH and Cy is methylphenyl;

in Subformula IIIn Q is (C=O)NH and Cy is fluoro, trifluoromethyl phenyl;

in Subformula IIIo Q is (C=O)NH and Cy is chlorophenyl or dichlorophenyl;

in Subformula IIIp Q is (C=O)NH and Cy is naphthyl;

in Subformula IIIq Q is (C=O)NH and Cy is norbornyl;

in Subformula IIIr Q is (C=O)NH and Cy is trifluoromethoxyphenyl.

6. The compound of claim 1, Formula IV, wherein:

X is NH, NH-C(=O), NH-CH_2, (-C=O)NH, NH-C(=O)NH, O, S, SO_2NH, CH_2, -C≡C-, or –HC=CH- ;

Y is O, S, or NH;

A is a 3-7 membered ring, saturated or unsaturated, optionally having 1 or more heteroatoms ~~and further optionally substituted~~;

Cy is selcted from the group consisting of ~~an unsubstituted or substituted~~ cycloalkyl, bicycloalkyl such as norbornyl, aryl, heterocycle and heteroaryl;

Z is ~~H,~~ SH, hydroxy, halo, amino, acyl, formyl, alkylamino-heterocycle, dialkylamino-heterocycle, alkylamino-alkylamino, dialkylamino-alkylamino, alkylamino-alkoxy, dialkylamino-alkoxy, heterocyclic alkoxy, C_{1-6} alkyl ester, phenyl, benzoyl, phenyl alkyl ketone, alkyl propanoyl, dialkyl alkanamide, acetic acid, or acetic acid amides;

Z' is C or N;

------ denotes the presence or absence of a bond;

R_1, R_2, R_3, each independently is H, SH or an ether or oxidated form of sulfur; halo, nitro, amino, alkyl, formyl, hydroxy, hydroxyalkyl, alkoxy cyano, carboxy, carboxylic acid, a carboxylic acid ester, a carboxylic acid amide

such as -(C=O)-N(RxRy), acetic acid, acetic acid ester, acetic acid amide including an acetic acid amide having substitutions -(C=O)-N(RxRy), substituted or unsubstituted aryl, heterocyclic-alkoxy, substituted or unsubstituted heterocycle or heteroaryl, alkylamino, dialkylamino, alkylaminoalkyl, dialkylaminoalkyl, alkyldiamino, alkylaminoalkoxy, alkyldiaminoalkoxy, heterocyclic-alkoxy, alkylamino amide, dialkylamino amide carboxylic acid ester, hydroxyalkyl-hydroxy, hydroxy-alkylamide ester, dihydroxy-alkylamide ester, hydroxyalkylamide acetic acid; wherein Rx and Ry each independently may be H, alkyl, aminoalkyl, dialkylaminoalkyl, aryl-aminoalkyl, carbocycle-aminoalkyl, or heteroaryl-amino alkyl; and wherein the two groups bonded to the N atom of an aminoalkyl group may, together with the N atom to which they are bound, join to form a heterocyclic group; or

a pharmaceutically acceptable salt, ~~prodrug,~~ hydrate, solvate, tautomer, racemic mix, or enantiomer thereof.

7. The compound of claim 6 wherein the residues not designated in greater detail have the meaning indicated in claim 6, but in which

in Subformula IVa R_1 is H, X is NH, A is phenyl, Cy is phenyl, and Z is 4-dimethyl amino-piperidine;

in Subformula IVb R_1 is H, X is NH, A is phenyl, Cy is phenyl, and Z is dimethylamino-ethylamine;

in Subformula IVc Z is dimethylamino-propylamine;

in Subformula IVd Z is dimethylamino-pyrrolidine;

in Subformula IVe Z is dimethylaminoethoxy or dimethylaminopropoxy;

in Subformula IVf Z is pyrrolidinyl ethoxy or pyrrolidinyl propoxy;

in Subformula IVg W is O, Y is O, X is NH, A is phenyl, Cy is difluorophenyl, R_1 is phenyl and/or carboxylic acid;

in Subformula IVh W is O, Y is O, X is NH, A is phenyl, Cy is difluorophenyl, and R_1 is dimethylamino ethyl carboxylic acid amide;

in Subformula IVj W is O, Y is O, X is NH, A is phenyl, Cy is difluorophenyl, and Z is dihydroxypropyl carboxylic acid amide;

in Subformula IVk W is O, Y is O, X is NH, A is phenyl, Cy is difluorophenyl, and R_2 is methyl acetic acid;

in Subformula IVm W is O, Y is O, X is NH, A is phenyl, Cy is

~~difluorophenyl, and R_2 is hydroxyethyl acetic acid amide.~~

8. A pharmaceutical composition comprising a compound of Formula III, IV or I according to one or more of claims 1 - 7, and a physiologically acceptable carrier, diluent, or excipient.

~~9. A composition of claim 8 wherein the compound is present in an amount of from about 0.1 – 1000 mg.~~


~~10. A composition of claim 9 wherein the compound is present in an amount from about 0.1 – 500 mg.~~

~~11. A composition of claim 8 that is the form of a tablet, capsule, powder, suspension, aerosol, spray, granulate, solution, or paste.~~


~~12. A composition of claim 8 that is administered orally, parenterally, intradermally, intranasally, subcutaneously, intrabuccally, intravenously, intramuscularly, or iontophoretically.~~

~~13~~9. A process for preparing a compound of claim 1 comprising the steps of:

a. reacting a compound intermediate of the Formula V, VI, or VII:



(V) ,



(VI) , or



(VII) ,

wherein:

B is 4 – 10 membered, saturated or unsaturated, ring that may be mono-, bi-, or tricyclic, and optionally may have one or more heteroatoms;

D is phenyl, a carbocycle, or a heterocycle, any of which optionally is substituted;

Z is H, SH, hydroxy, halo, amino, acyl, formyl, alkylamino-heterocycle, dialkylamino-heterocycle, alkylamino-alkylamino, dialkylamino-alkylamino, alkylamino-alkoxy, dialkylamino-alkoxy, heterocyclic alkoxy, C_{1-6} alkyl ester, phenyl, benzoyl, phenyl alkyl ketone, alkyl propanoyl, dialkyl alkanamide, or acetic acid; and


R and W have the same meanings as given for Formulae I, II, III and IV;

with t-butyl COCl in the presence of TEA to provide a first intermediate product that is a t-butyl carboxamide substituted pyridine;

b. reacting the first intermediate product with butyl lithium in DMF to provide a second intermediate product that is an optionally substituted acetyl, *t*-butyl carboxamide substituted pyridine;

c. reacting the second intermediate product with t-butyl methyl ester in the presence of LDA to provide a third intermediate product that is a pyridine having t-butyl carboxylic acid ester hydroxymethyl and t-butyl carboxamide substituents, and that may be further substituted;

d. refluxing the third intermediate product with aqueous HCl to provide a fourth intermediate of the Formula VIII:



(VIII) , and

e. reacting the compound of Formula VIII with a bis-phenyl carboxamide wherein one phenyl is substituted by an amino group and the other phenyl is optionally substituted, in the presence of Pd and X-phosphate to provide the final product compound.

~~14. A method of treating a proliferative, autoimmune, anti-inflammatory or infectious disease disorder that comprises administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.~~

~~10.~~ ~~A compound of one or more of claims 1 – 7 for use in the treatment of a proliferative, autoimmune, anti-inflammatory or infectious disease disorder that comprises administering to a subject in need thereof a therapeutically effective amount of.~~

~~15~~11. The ~~method~~ compound of claim ~~14~~10 wherein the disorder is selected from the group consisting of angiogenesis, cancers, tumors, arteriosclerosis, ocular disease, arthritis, thrombosis, fibrosis, glomerulonephritis, psoriasis, restenosis, transplant rejection, cirrhosis, viral and bacterial infections, and autoimmune disease.

~~16~~12. The ~~method~~ compound of claim ~~15~~11 wherein the disease is a cancer.

~~17. The method of claim 14 wherein the subject is a mammal.~~

~~18. The method of claim 17 wherein the mammal is a human.~~

~~19~~13. The ~~method~~ compound of claim ~~14~~10 wherein administration is simultaneous, sequential or in alternation with administration of at least one other active drug agent.

~~20~~14. A kit comprising separate packets, the first having a therapeutically effective amount of a pharmaceutical composition according to claim 8, and the second having a therapeutically effective amount of a pharmaceutical composition comprising a further pharmaceutically active ingredient.

~~21~~15. The compound of claim 1 selected from the group consisting of ~~N-(4-aminophenyl)-2-fluoro-benzamide; N-(5-amino-pyrimidin-2-yl)-benzamide; N-(4-aminophenyl)-3-fluoro-benzamide; N-(4-aminophenyl)-2-trifluoromethyl-benzamide; N-(4-aminophenyl)-2-trifluoromethyl-benzamide; N-(4-aminophenyl)-4-trifluoromethyl-benzamide; N-(4-aminophenyl)-2-fluoro-3-trifluoromethyl-benzamide; N-(4-aminophenyl)-4-fluoro-2-trifluoromethyl-benzamide; N-(4-aminophenyl)-2,6-difluoro-benzamide; N-(4-aminophenyl)-3,4-difluoro-benzamide; N-(4-aminophenyl)-3,5-difluoro-benzamide; N-(4-aminophenyl)-2,4-difluoro-benzamide; cyclohexanecarboxylic acid (4-aminophenyl)-amide; N-(4-aminophenyl)-3,5-bis-trifluoromethyl-benzamide; naphthalene-2-carboxylic acid (4-aminophenyl)-amide; N-(4-aminophenyl)-2-methoxy-benzamide; N-(4-aminophenyl)-4-methyl-benzamide; N-(4-aminophenyl)-2-fluoro-4-trifluoromethyl-benzamide; N-(4-~~

aminophenyl)-3-fluoro-5-trifluoromethyl-benzamide; N-(4-aminophenyl)-4-chloro-benzamide; N-(4-aminophenyl)-4-trifluoromethoxy-benzamide; N-(4-aminophenyl)-2-methyl-benzamide; N-(4-aminophenyl)-3-methyl-benzamide; naphthalene-1-carboxylic acid-(4-aminophenyl)-amide; N-(4-aminophenyl)-2,6-dichloro-benzamide; N-(4-aminophenyl)-3,4-dichloro-benzamide; N-(4-aminophenyl)-2,4-dichloro-benzamide; N-(4-chloropyridin-2-yl)-2,2-dimethylpropanamide; N-(4-chloro-3-formylpyridin-2-yl)-2,2-dimethylpropanamide; tert-butyl 3-{4-chloro-2-[(2,2-dimethylpropanoyl)amino]pyridin-3-yl}-3-hydroxypropanoate; 5-chloro-1,8-naphthyridi-2(1*H*)-one; N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)pyrimidin-2-yl)benzamide; 2-fluoro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 3-fluoro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 4-fluoro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 2-trifluoromethyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 4-trifluoromethyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 2-fluoro-3-Trifluoromethyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 4-flouro-2-trifluoromethyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 2,6-diflouro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 3,4-diflouro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 3,5-diflouro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 2,4-diflouro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)cyclohexanecarboxamide; N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yloxy)phenyl)benzamide; N-(2-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-ylamino)phenyl)benzamide; 4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-ylamino)-N-phenyl-benzamide; 3,5-bis(trifluoromethyl)-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-naphthalen-2-yl-4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)benzamide; 2-methoxy-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 4-methyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 2-fluoro-4-trifluoromethyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 3-fluoro-5-trifluoromethyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 4-chloro-N-(4-(7-oxo-7,8-dihydro-1,8-

naphthyridin-4-yl-amino)phenyl)benzamide; 4-trifluoromethoxy-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 2-methyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 3-methyl-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-naphthalen-1-yl-4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)benzamide; 2,6-dichloro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 3,4-dichloro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; 2,4-dichloro-N-(4-(7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-chloro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7(4-dimethylamino-piperidin-1-yl-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(4-dimethylamino-ethylamino)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(4-dimethylamino-propylamino)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(4-dimethylamino-pyrrolidin-1-yl)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(4-dimethylamino-ethoxy)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(4-dimethylamino-propoxy)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(2-pyrrolidin-1-yl-ethoxy)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(3-morpholin-4-yl-propoxy)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; N-(4-(7-(2-morpholin-4-yl-ethoxy)-1,8-naphthyridin-4-yl-amino)phenyl)benzamide; ~~N-(3-benzoyl-4-chloropyridin-2-yl)-2,2-dimethylpropanamide; (2-amino-4-chloro-pyridin-3-yl)-phenyl-methanone; 5-chloro-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridi-3-carboxylic acid tert-butyl ester;~~ 5-[(3,4-diflouro-benzoylamino)-phenylamino]-2-oxo-4-phenyl1,2-dihydro-1,8-naphthyridine-3-carboxylic acid; 5-[(3,4-diflouro-benzoylamino)-phenylamino]-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide; 5-[(3,4-diflouro-benzoylamino)-phenylamino]-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridine-3-carboxylic acid (2-hydroxy-ethyl)-amide; 5-[(3,4-diflouro-benzoylamino)-phenylamino]-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridine-3-carboxylic acid ((S)2,3-dihydroxypropyl)-amide; ~~(5-chloro-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl)-acetic acid;~~ 5-[(3,4-diflouro-benzoylamino)-phenylamino]-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridine-3-acetic acid; and 5-[(3,4-diflouro-benzoylamino)-phenylamino]-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridine-3-acetic acid (2-hydroxy-ethyl)-amide, 3,4-Difluoro-N-(4-(6-nitro-7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl amino)phenyl)benzamide, 4-Fluoro-2-trifluoromethyl-N-(4-(6-nitro-7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-

amino)phenyl)benzamide, 3,4-Difluoro-N-(4-(6-amino-7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide, 4-Fluoro-2-trifluoromethyl-N-(4-(6-amino-7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl-amino)phenyl)benzamide, 4-Fluoro-N-[4-(5-hydroxy-7-oxo-7,8-dihydro-[1,8]naphthyridin-4-ylamino)-phenyl]-2 trifluoromethyl-benzamid, N-[4-(5-Hydroxy-7-oxo-7,8-dihydro-[1,8]naphthyridin-4-ylamino)-phenyl]-benzamide, N-[4-(5-Cyclopropylmethoxy-7-oxo-7,8-dihydro-[1,8]naphthyridin-4-ylamino)-phenyl] benzamide, N-[4-(5-Methyl-7-oxo-7,8-dihydro-[1,8]naphthyridin-4-ylamino)-phenyl]-benzamide, 4-Fluoro-N-[4-(5-methyl-7-oxo-7,8-dihydro-[1,8]naphthyridin-4-ylamino)-phenyl]-2 trifluoromethyl-benzamide, 4-Fluoro-N-[4-(6-fluoro-7-oxo-7,8-dihydro-[1,8]naphthyridin-4-ylamino)-phenyl]-2 trifluoromethyl-benzamide.